Celgene Corp (CELG) 102.91 $CELG SmarTrend Watching for

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 8:20 AM

Celgene Corp (CELG) 102.91 $CELG

SmarTrend Watching for Potential Rebound in Shares of Celgene After 2.63% Loss
Comtex SmarTrend(R) - Fri Jun 10, 12:32PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $103.26 to a high of $105.47. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $105.65 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 102.91 (-3.22)

Watch for Celgene to Potentially Rebound After Falling 2.63% Yesterday
Comtex SmarTrend(R) - Fri Jun 10, 12:30PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $103.26 to a high of $105.47. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $105.65 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 102.91 (-3.22)

Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 35.44 (+0.94), CELGZ: 1.46 (-0.04), CELG: 102.91 (-3.22)

Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
BusinessWire - Thu Jun 09, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that more than 40 presentations reporting on investigational studies in blood cancers will be presented during the 21st European Hematology Association annual meeting in Copenhagen, Denmark, from June 9-12, 2016.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)

Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 246.13 (-4.33), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), REGN: 372.03 (-9.05), CELG: 102.91 (-3.22)

Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
BusinessWire - Tue Jun 07, 3:05PM CDT
Celgene Corporation (NASDAQ:CELG) today announced the presentation of a study comparing treatment patterns, healthcare costs and overall survival between African American and Caucasian Medicare beneficiaries with newly diagnosed multiple myeloma. The study, which was presented by Dr. Sikander Ailawadhi of the Mayo Clinic at a poster session during the 52nd ASCO Annual Meeting in Chicago, Ill, discussed disparities observed in treatment initiation between the two studied populations and the impact of these disparities on patient outcomes.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)

Next Support Level for Celgene (CELG) is $105.58
Comtex SmarTrend(R) - Tue Jun 07, 9:11AM CDT
Celgene (NASDAQ:CELG) has opened bearishly below the pivot of $107.56 today and has reached the first level of support at $106.61. Investors may be interested in a cross of the next downside pivot targets of $105.58 and $103.60.
CELG: 102.91 (-3.22)

Data Presented at ASCO 2016 Builds upon Foundation of Abraxane(R) Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer
BusinessWire - Sat Jun 04, 4:32PM CDT
Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored and independent studies presented during the 52nd ASCO Annual Meeting evaluated the use of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) in combination with gemcitabine in first-line metastatic pancreatic cancer.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)

Corcept (CORT) Reports Early Breast Cancer Data on Korlym
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 4:06PM CDT
Corcept (CORT) released preliminary efficacy data from a phase I/II study on Korlym for the treatment of treat triple-negative breast cancer (TNBC).
PFE: 35.29 (-0.02), BMY: 72.65 (-0.08), CORT: 5.60 (+0.13), CELG: 102.91 (-3.22)

Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID(R) Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma
BusinessWire - Fri Jun 03, 3:59PM CDT
Celgene Corporation (NASDAQ:CELG) today announced data from a meta-analysis of overall survival in multiple myeloma (MM) patients receiving investigational maintenance treatment with REVLIMID(R) (lenalidomide) capsules following high-dose melphalan and autologous stem cell transplant (ASCT) were presented during the 52nd ASCO Annual Meeting in Chicago, Illinois. The analysis, based on data from studies conducted by the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group with support from the National Cancer Institute, Intergroupe Francophone du Myelome (IFM) and the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), was presented by Dr. Philip McCarthy of Roswell Park Cancer Institute and lead investigator of the CALGB (Alliance) 100104 study. The findings demonstrated significantly prolonged overall survival (OS) compared to the control arm of placebo or no maintenance.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)

Downgrade Alert for Celgene (CELG)
Comtex SmarTrend(R) - Thu Jun 02, 3:27AM CDT
Celgene (NASDAQ:CELG) was downgraded from Buy to Neutral at BTIG today. The stock closed yesterday at $106.02 on volume of 2.9 million shares, below average daily volume of 4.7 million. There is potential upside of 36.3% for shares of Celgene based on a current price of $106.02 and an average consensus analyst price target of $144.47. Celgene shares should encounter resistance at the 200-day moving average (MA) of $112.65 and support at the 50-day MA of $103.40.
CELG: 102.91 (-3.22)

InvestorsObserver releases covered-call reports for GoPro, Verizon Communications, Vertex Pharmaceuticals, NVIDIA and Celgene
PR Newswire - Tue May 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, VZ, VRTX, NVDA and CELG.
GPRO: 10.26 (-0.64), VRTX: 91.49 (-1.00), VZ: 52.67 (+0.72), NVDA: 46.20 (-1.18), CELGZ: 1.46 (-0.04), CELG: 102.91 (-3.22)

Look for Shares of Celgene to Potentially Pullback after Yesterday's 2.38% Rise
Comtex SmarTrend(R) - Tue May 24, 2:15PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $101.32 to a high of $103.85. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $102.41 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 102.91 (-3.22)

SmarTrend Watching for Potential Pullback in Shares of Celgene After 2.38% Gain
Comtex SmarTrend(R) - Tue May 24, 2:14PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $101.32 to a high of $103.85. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $102.41 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 102.91 (-3.22)

Celgene Corporation to Webcast at Upcoming Investor Conferences
BusinessWire - Fri May 20, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and the webcast will be available in the Investor Relations section of the Company's website at www.celgene.com.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)

Watch for Celgene to Potentially Rebound After Falling 1.28% Yesterday
Comtex SmarTrend(R) - Thu May 19, 1:15PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $99.03 to a high of $100.92. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $99.76 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 102.91 (-3.22)

Celgene Falls 1.28% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu May 19, 1:13PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $99.03 to a high of $100.92. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $99.76 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 102.91 (-3.22)

Celgene, Yahoo!, American Airlines, Exxon Mobil, and Skyworks Solutions and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Thu May 19, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CELG, YHOO, AAL, XOM and SWKS.
YHOO: 36.83 (-0.52), SWKS: 65.55 (-2.42), XOM: 89.98 (-0.69), AAL: 33.14 (-0.26), CELGZ: 1.46 (-0.04), CELG: 102.91 (-3.22)

Rexahn's Drugs Deal a Death Blow to Solid Tumor Cancer
ACCESSWIRE - Thu May 19, 8:01AM CDT
Efficacy in Gemzar-resistant cancer is proven
RNN: 0.27 (-0.01), OGXI: 1.08 (+0.07), AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48), BMY: 72.65 (-0.08), MNTA: 11.67 (-0.13), CELG: 102.91 (-3.22), EXEL: 7.38 (+0.01)

Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2016
BusinessWire - Wed May 18, 4:43PM CDT
Celgene Corporation (NASDAQ:CELG) today announced more than 65 presentations reporting on investigational studies in blood and solid tumor cancers will be presented during the 52ndAmerican Society of Clinical Oncology meeting in Chicago, Ill. from June 3-7, 2016.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Coastal Construction Revamps South Florida's Equipment Game

Revolutionizing Equipment Acquisition in South Florida Looks like the sun's shining a bit differently on South Florida's contractors. Coastal Construction Equipment, LLC just announced their big debut as a new player on the Cat Compact™ scene, turning the tides for those in the construction industry. With a plan that's as big as a bulldozer, they'll be breaking ground,...

Andersen 400 Series Patio Door Wins 2027 Award

Andersen's Winning Streak Continues Ever got that feeling when you see an old player pulling off a brand-new trick in the game they love? That's kind of what Andersen Windows just pulled off with their 400 Series patio door snagging the 2027 Home Reno Award from Good Housekeeping. You could say Andersen's figured out how to keep the classics fresh without losing that...

International Tower Hill's Q3 Results: Gold Updates

An Eye on International Tower Hill's Latest Moves You've got International Tower Hill Mines (TSX: ITH, NYSE American: THM) laying their cards on the table for the third quarter. This ain't just any routine check-in—it's a glimpse at their Livengood Gold Project, standing tall on the promise of gold beyond the horizon. A cool $106 million in cash? Not too shabby, folks....

Welders Breathe Easier with New Helmet Innovation

Breathing Easy in the Welding Sector There's a new contraption sizzling into the welding world, and it’s not sparks flying from a torch, but rather an innovative helmet design that aims to shield workers from the all-too-common health hazards in their line of work. Yes, you heard it right: a breath of fresh air for welders, literally. An inventor from Zanesville, Ohio,...

Kavalan Whisky Expands into Ghana with Say Cheers

A Taste of Taiwan in Ghana The whisky world just got a bit smaller with Kavalan’s latest move If you know whisky, you know Kavalan, the Taiwanese gem that's been steadily building its global footprint. And now, they've set their sights on Ghana. Yup, this one's not about rattling sabers but raising glasses! Partnering with Say Cheers Limited, Kavalan enters Ghana,...

Terracon and Brickeye Join Forces to Reduce Concrete Risks

Concrete Hassles Get Innovative Solutions Terracon and Brickeye have decided to work together to solve one of construction's nastiest headaches—mass concrete risks. It's a world where small mishaps can snowball into massive, costly blowbacks. Solid Partnership for a Solid Solution We're not talking about some half-baked fling here. This partnership is the real deal,...

Suiteify Teams Up With Findity for German Launch

Striking a Partnership That Makes Sense Today's deal rolls in like thunder on a quiet afternoon. Suiteify, the master of HR and business software in the DACH region, hooks up with Findity to unleash a new game-changer in Germany. They’re cooking up Suiteify Expense & Travel, and if you're in the mid-sized business space, it’s worth a pause to see how these two horses...

Quantinuum & RIKEN Propel Japan's Quantum Leap Forward

Quantum Computing: Japan's Bold New Frontier Quantum computing's buzz is getting louder, and the big players like Quantinuum and RIKEN ain't sitting on their hands. They've rolled up their sleeves to ramp up Japan's quantum-AI supercomputing game with the recent beef-up of Quantinuum's Reimei to its H2 system, putting Japan at the cutting edge of hybrid computing. The...

Outdoor Learning: Sparking Preschool Curiosity Weekly

Rekindling Curiosity in Nature’s Classroom With autumn’s crisp air rolling into Greenville, families have a golden opportunity to take learning beyond the traditional classroom. Archway Academy sees the beauty of this season as a sprawling classroom, one that doesn't confine young minds and bodies. For those of us focused more on dollars and sense, the financial...

Jacobite Steam Train Redefines the Harry Potter Experience

Turn Fantasy into Reality: A Ride Unlike Any Other Ever fantasized about stepping right into the pages of your favorite tale? Well, the Jacobite Steam Train gives Potterheads just that: a literal ride through Harry Potter’s world, but in the heart of Scotland. As HBO's fresh take on the Harry Potter series is about to drop this Christmas, the buzz is lining the tracks...